- Home
- GPOR vs CNTA Comparison
GPOR vs CNTA Comparison
Compare GPOR & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPOR | CNTA |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.5B |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GPOR | CNTA |
|---|---|---|
| Price | $205.99 | $39.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $232.44 | $42.00 |
| AVG Volume (30 Days) | 309.9K | ★ 4.0M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 245.92 | 29.13 |
| EPS | ★ 21.48 | N/A |
| Revenue | ★ $1,422,583,000.00 | $15,000,000.00 |
| Revenue This Year | $15.96 | N/A |
| Revenue Next Year | $7.28 | N/A |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | ★ 48.47 | N/A |
| 52 Week Low | $153.41 | $9.60 |
| 52 Week High | $225.78 | $40.26 |
Technical Indicators
Market Signals| Indicator | GPOR | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 77.47 |
| Support Level | $192.50 | $22.49 |
| Resistance Level | $216.51 | N/A |
| Average True Range (ATR) | 8.14 | 1.42 |
| MACD | -0.10 | 1.33 |
| Stochastic Oscillator | 45.83 | 96.39 |
Price Performance
Historical ComparisonAbout GPOR Gulfport Energy Corporation
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets predominantly located in the Appalachia and Anadarko basins in the United States. Its principal properties are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.